Do glp-1s work for parkinson's? A health tech startup pitches pharma on quick answers

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is

changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You

can reach Mario on Signal at mariojoze.13. NEW YORK — On the 77th floor of One World Trade Center, in an office with panoramic views of Manhattan, executives from pharma and biotech

companies like Regeneron and Merck heard the pitch: Please help us study GLP-1s in Parkinson’s disease. With the explosion in popularity of diabetes and weight loss drugs like Ozempic and

Zepbound, GLP-1 receptor agonist drugs have been hyped as potential miracle cures for many diseases. GLP-1s are being studied for cardiovascular disease, liver conditions, kidney disease,

and Alzheimer’s. Older approved GLP-1s from Novo Nordisk, Sanofi, and Amylin have been or are being explored for Parkinson’s. But amid all the jostling to find the next use case for GLP-1s,

the proposition in October — the day before the Michael J. Fox Foundation’s annual meeting in New York — came from an unlikely source: Koneksa Health, which helps drug developers use

smartphone apps and wearables to study whether their treatments work. Koneksa hatched a plan to study GLP-1 with its tools after researchers in April published results of a randomized

control trial showing that people with Parkinson’s on Sanofi GLP-1 drug Lixisenatide saw no worsening of motor symptoms over a year, compared to those on placebo who did.  STAT+ Exclusive

Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — AND GET ADDITIONAL ANALYSIS OF THE TECHNOLOGIES DISRUPTING HEALTH CARE — BY

SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe